Latest technologies for the enhancement of antibody affinity
- PMID: 16828920
- DOI: 10.1016/j.addr.2006.01.025
Latest technologies for the enhancement of antibody affinity
Abstract
High affinity antibodies are crucial both for the discovery and validation of biomarkers for human health and disease and as clinical diagnostic and therapeutic reagents. This review describes some of the latest technologies for the design, mutation and selection of high affinity antibodies that provide a paradigm for molecular evolution of a far wider range of proteins including enzymes. Strategies include both in vivo and in vitro methods and embrace the latest concepts for antibody display and selection. Specifically, affinity enhancement can be tailored to the target-binding surface, typically the complementary determining region (CDR) loops in antibodies, whereas enhanced stability, expression or catalytic properties can be affected by selected changes to the core protein scaffold. Together, these technologies provide a rapid and powerful strategy to drive the next generation of protein-based reagents for numerous clinical, environmental and agribusiness applications.
Similar articles
-
Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies.J Mol Biol. 2007 May 11;368(4):1024-41. doi: 10.1016/j.jmb.2007.02.029. Epub 2007 Feb 22. J Mol Biol. 2007. PMID: 17382960
-
Ribosome display: next-generation display technologies for production of antibodies in vitro.Expert Rev Proteomics. 2005 Jun;2(3):421-30. doi: 10.1586/14789450.2.3.421. Expert Rev Proteomics. 2005. PMID: 16000087 Review.
-
Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions.J Mol Biol. 2009 May 8;388(3):541-58. doi: 10.1016/j.jmb.2009.03.019. Epub 2009 Mar 13. J Mol Biol. 2009. PMID: 19285987
-
A new generation of protein display scaffolds for molecular recognition.Protein Sci. 2006 Jan;15(1):14-27. doi: 10.1110/ps.051817606. Protein Sci. 2006. PMID: 16373474 Free PMC article. Review.
-
Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.Mol Immunol. 2008 May;45(9):2474-85. doi: 10.1016/j.molimm.2008.01.016. Epub 2008 Mar 3. Mol Immunol. 2008. PMID: 18313757
Cited by
-
Automated screening of monoclonal antibodies for SISCAPA assays using a magnetic bead processor and liquid chromatography-selected reaction monitoring-mass spectrometry.J Immunol Methods. 2010 Feb 28;353(1-2):49-61. doi: 10.1016/j.jim.2009.11.017. Epub 2009 Dec 1. J Immunol Methods. 2010. PMID: 19961853 Free PMC article.
-
A mechanistic PK/PD model for two anti-IL13 antibodies explains the difference in total IL-13 accumulation observed in clinical studies.MAbs. 2016 Jul;8(5):983-90. doi: 10.1080/19420862.2016.1172151. Epub 2016 Apr 6. MAbs. 2016. PMID: 27049478 Free PMC article. Clinical Trial.
-
Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies.MAbs. 2009 May-Jun;1(3):254-67. doi: 10.4161/mabs.1.3.8035. Epub 2009 May 29. MAbs. 2009. PMID: 20065649 Free PMC article.
-
In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF165 neutralization.Oncotarget. 2018 Jun 15;9(46):28016-28029. doi: 10.18632/oncotarget.25549. eCollection 2018 Jun 15. Oncotarget. 2018. PMID: 29963259 Free PMC article.
-
Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools.Biomark Res. 2025 Mar 29;13(1):52. doi: 10.1186/s40364-025-00764-4. Biomark Res. 2025. PMID: 40155973 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources